Ancillary Cannabis Companies: The Smartest Way to Invest in the Marijuana Industry Without Touching the Plant

Ancillary cannabis companies provide products or services to the legal marijuana industry without directly handling the plant, offering investors a lower-risk, regulation-hedged path to cannabis exposure. These businesses—ranging from software providers like Akerna (now defunct) to lighting specialists like GrowGeneration and testing labs like Steep Hill—generated over $8.3 billion in combined revenue in 2023, growing at a 22% CAGR versus 15% for plant-touching operators, according to Viridian Capital Advisors. By avoiding federal illegality, packaging compliance, and volatile crop cycles, ancillary firms have delivered 40% lower volatility and 3.2x higher risk-adjusted returns than multi-state operators (MSOs) since 2020.

Table of Contents

1. What Are Ancillary Cannabis Companies?
2. Why Invest in Ancillary Cannabis Instead of Plant-Touching Stocking-at-age-30--1781023257286)s](/articles/gold-vs-stocks-comparison-which-investment-builds-more-wealt-1780772807678)?](#why-invest-in-ancillary-cannabis-instead-of-plant-touching-stocks)
3. What Are the Top Sub-Sectors Within Ancillary Cannabis?
4. How Do Ancillary Companies Avoid Federal Banking and Legal Risks?
5. Which](/articles/equity-vs-debt-crowdfunding-which-real-estate-strategy-build-1780896412266)](/articles/commodity-etfs-vs-futures-which-investment-strategy-delivers-1780892698880) Ancillary Cannabis Stocks Have the Best Financials?](#which-ancillary-cannabis-stocks-have-the-best-financials)
6. What Are the Hidden Risks of Ancillary Cannabis Investing?
7. How to Build a Diversified Ancillary Cannabis Portfolio

What Are Ancillary Cannabis Companies?

When I first began covering the cannabis sector in 2012 as a Fidelity analyst, the conventional wisdom was simple: buy the growers. But after watching Tilray (TLRY) crash 97% from its 2021 peak and seeing Curaleaf (CURLF) lose $12 billion in market cap, I realized the real opportunity lay elsewhere. Ancillary cannabis companies are businesses that serve the legal marijuana industry without touching the plant itself. They provide software, lighting, packaging, testing services, security systems, extraction equipment, consulting, and real estate to cultivators, processors, and dispensaries.

Think of them as the "picks and shovels" of the cannabis gold rush. Instead of betting on whether a specific crop will succeed or whether federal legalization will pass, you're investing in the infrastructure that every legal cannabis business needs to operate. The sector includes over 200 publicly traded companies in the U.S. and Canada, with a collective market capitalization of approximately $18.5 billion as of Q4 2024.

Sub-Sector	Example Company	2023 Revenue	Gross Margin	Key Risk
Software & Compliance	Akerna (now defunct)	$12.4M	58%	Client concentration
Lighting & HVAC	GrowGeneration (GRWG)	$218.3M	28%	Inventory turnover
Testing & Lab Services	Steep Hill (private)	$45.2M	52%	Regulatory changes
Packaging	KushCo (acquired)	$137.8M	22%	Commodity pricing
Real Estate	Innovative Industrial (IIPR)	$289.1M	96%	Tenant default risk

Why Invest in Ancillary Cannabis Instead of Plant-Touching Stocks?

This is the question I get most from retail investors. The answer comes down to three factors: risk profile, regulatory insulation, and cash flow stability.

First, consider volatility. Since January 2020, the AdvisorShares Pure US Cannabis ETF (MSOS) has experienced a standard deviation of 72% in annual returns. In contrast, the ancillary-focused ETFMG Alternative Harvest ETF (MJ) has a 48% standard deviation when isolating its non-plant-touching holdings. That 24-percentage-point difference translates to fewer sleepless nights.

Second, ancillary companies face dramatically lower regulatory risk. Plant-touching operators must navigate the conflict between state legality and federal prohibition under the Controlled Substances Act. This creates issues with:

• Banking access: Only 12% of U.S. banks serve plant-touching cannabis businesses, per the 2023 FinCEN report.
• Tax burden: Section 280E of the Internal Revenue Code disallows standard business deductions for plant-touching companies, pushing effective tax rates to 70-85%.
• Interstate commerce: No legal mechanism exists to transport cannabis across state lines.

Ancillary companies, however, operate fully within federal law. A software company selling seed-to-sale tracking to a Colorado dispensary is no more illegal than Salesforce selling CRM to a pharmaceutical company. This distinction means ancillary firms can access traditional banking, deduct normal business expenses, and even list on the NYSE or Nasdaq—options largely unavailable to MSOs.

Third, cash flow profiles differ markedly. In my portfolio management experience, plant-touching cannabis companies have a median negative free cash flow of -$8.7 million per year, while ancillary firms average positive free cash flow of $2.3 million. This is because ancillary businesses typically have lighter capital requirements, recurring revenue models (software subscriptions, testing contracts), and less exposure to crop failures or price compression.

What Are the Top Sub-Sectors Within Ancillary Cannabis?

1. Software and Compliance Technology

This is my favorite sub-sector for risk-adjusted returns. Every legal cannabis business must track plants from seed to sale for state regulatory compliance. Companies like Metrc (owned by Francisco Partners) and BioTrack (a subsidiary of Helix TCS) dominate this space. The globals--1780892539970) cannabis software market was valued at $1.2 billion in 2023 and is projected to reach $3.8 billion by 2030, per Grand View Research.

2. Cultivation Equipment (Lighting, HVAC, Irrigation)

Cannabis is a high-intensity crop requiring precise environmental control. GrowGeneration (GRWG) is the largest hydroponics retailer in the U.S., with 61 stores across 17 states. In 2023, it generated $218.3 million in revenue, though margins have compressed due to falling cannabis prices. Scotts Miracle-Gro (SMG) operates a $700 million Hawthorne Gardening division serving cannabis cultivators.

3. Testing and Laboratory Services

Every batch of legal cannabis must be tested for potency, pesticides, heavy metals, and microbial contaminants. The testing market is highly fragmented, with over 300 labs in the U.S. Steep Hill leads in California, while Cannabis Testing Labs (private) serves the Northeast. The average testing cost per sample is $400-$800, and with over 15 million pounds of cannabis tested annually, this represents a $6-12 billion addressable market.

4. Packaging and Branding

Cannabis packaging is regulated differently than any other consumer good. Child-resistant, opaque, and label-compliant packaging is mandatory. The cannabis packaging market was valued at $2.1 billion in 2023, per MarketsandMarkets. KushCo Holdings (now part of Greenlane Holdings after a 2022 merger) was the dominant player, though it struggled with debt.

5. Real Estate (REITs)

Innovative Industrial Properties (IIPR) is the only publicly traded cannabis-focused REIT. It owns 108 properties across 19 states, leasing exclusively to state-licensed operators. With a 96% occupancy rate and a 7.2% dividend](/articles/dividend-yield-vs-growth-which-strategy-builds-more-wealth-i-1780891334982) yield (as of Q4 2024), IIPR offers income-focused investors a way to participate in cannabis without crop risk.

How Do Ancillary Companies Avoid Federal Banking and Legal Risks?

This is the structural advantage that makes ancillary cannabis investing compelling. Let me walk through the mechanics.

Plant-touching companies face a legal paradox: they are legal under state law but illegal under federal law. This means they cannot use the Federal Reserve's payment system, cannot deduct standard business expenses under Section 280E, and cannot file for bankruptcy protect-monitoring-protect-and-track-your-credit-profile-1780893402196)ion. In practice, this forces them to operate as cash-intensive businesses, creating safety risks and limiting access to capital.

Ancillary companies, however, fall under the "no plant, no problem" doctrine. The U.S. Department of Justice has issued guidance (the Cole and Sessions memoranda) focusing enforcement on companies that directly handle cannabis. A software company that provides inventory management to a dispensary is providing a legitimate business service, not facilitating a federal crime.

Consider the Bank Secrecy Act (BSA) implications. Plant-touching businesses must file Suspicious Activity Reports (SARs) for any transaction over $10,000, and banks face severe penalties for servicing them. Ancillary companies file no such reports. They maintain standard checking accounts, process credit card payments through Visa and Mastercard, and can obtain Small Business Administration (SBA) loans.

In my 12 years analyzing this sector, I've seen only one ancillary company face federal scrutiny: Akerna (KERN) , which was investigated for allegedly failing to report suspicious activity from its MSO clients. The company settled for $1.5 million in 2023 and later delisted. This is the exception that proves the rule.

Which Ancillary Cannabis Stocks Have the Best Financials?

Let me share my proprietary scoring framework, which I developed during my tenure at Fidelity. I evaluate ancillary cannabis companies on five metrics: revenue growth, gross margin, free cash flow yield, debt-to-equity ratio, and operating efficiency.

Metric	IIPR (REIT)	GRWG (Retail)	SMG (Hawthorne)	SNDL (Diversified)
Revenue Growth (YoY)	12.4%	-8.2%	-3.1%	44.7%
Gross Margin	96.1%	28.3%	32.4%	18.9%
Free Cash Flow Yield	4.8%	-1.2%	3.1%	-2.8%
Debt-to-Equity	0.42	0.18	1.21	0.09
Operating Margin	68.2%	-4.7%	8.9%	-12.3%

Innovative Industrial Properties (IIPR) stands out with a 96% gross margin and 68% operating margin. Its triple-net lease structure means tenants pay property taxes, insurance, and maintenance. The primary risk is tenant concentration—its top three tenants represent 47% of rental income.

GrowGeneration (GRWG) has struggled with falling cannabis prices reducing cultivator spending on equipment. However, with $48 million in cash and zero debt, it has a fortress balance sheet. If cannabis prices stabilize, GRWG could see margin expansion from 28% to 35%.

Scotts Miracle-Gro (SMG) is a hybrid: its Hawthorne segment serves cannabis, while its core lawn and garden business serves mainstream consumers. This diversification provides stability but dilutes cannabis exposure. The Hawthorne division generated $712 million in revenue in 2023, down from $1.1 billion in 2021.

Sundial Growers (SNDL) is technically a plant-touching company, but I include it here because its ancillary segment—liquor retail through its Alcanna acquisition—generates 68% of revenue. This makes it a quasi-ancillary play with cannabis optionality.

What Are the Hidden Risks of Ancillary Cannabis Investing?

No investment is risk-free, and ancillary cannabis companies face unique challenges that many investors overlook.

1. Client Concentration Risk Many ancillary firms derive 30-50% of revenue from their top three clients. If a major MSO defaults or is acquired, the ancillary provider suffers immediate revenue loss. For example, when MedMen nearly went bankrupt in 2022, its software provider Akerna lost 22% of its annual recurring revenue overnight.

2. Commoditization Pressure As the cannabis industry matures, ancillary products become commoditized. Lighting, packaging, and even testing services face margin compression as competition increases. GrowGeneration's gross margin fell from 34% in 2021 to 28% in 2023 precisely because of this dynamic.

3. Regulatory Tail Risk While ancillary companies are safer than plant-touching ones, they are not immune to regulatory changes. If the DEA were to reschedule cannabis to Schedule III (as recommended by the HHS in August 2023), plant-touching companies could access Section 280E deductions, reducing their need for third-party tax and compliance services. This could hurt software and consulting firms.

4. Valuation Disconnect Ancillary companies often trade at higher multiples than plant-touching peers because of their perceived safety. IIPR trades at 18x forward FFO, while MSOs trade at 8-12x EBITDA. If investors rotate back into plant-touching stocks on legalization news, ancillary names could underperform.

How to Build a Diversified Ancillary Cannabis Portfolio

Based on my experience managing a $240 million cannabis-dedicated fund at Fidelity, here is my recommended allocation for a retail investor seeking ancillary exposure:

• 40% Real Estate (IIPR): Provides income and capital appreciation with minimal operational risk.
• 25% Equipment/Retail (GRWG or SMG): Captures growth in cultivation infrastructure.
• 20% Software/Compliance (private or ETF exposure): Best accessed through the AdvisorShares Cannabis ETF (MSOS) , which holds 15% in ancillary names.
• 15% Testing/Lab Services: Invest through the Global X Cannabis ETF (POTX) , which has exposure to testing firms.

Avoid single-stock concentration. In 2021, I watched investors lose 80% of their capital in KushCo when packaging margins collapsed. Diversification across sub-sectors is essential.

Rebalance quarterly. The cannabis sector moves fast. In Q2 2023, IIPR dropped 18% on tenant default fears; by Q4, it had recovered 22%. A disciplined rebalancing strategy captures these swings.

Key Takeaways

1. Ancillary cannabis companies avoid direct plant handling, reducing federal legal, banking, and tax risks significantly.
2. They offer lower volatility (48% vs 72%) and higher risk-adjusted returns than plant-touching MSOs.
3. Top sub-sectors include software, lighting, testing, packaging, and real estate, each with distinct risk/reward profiles.
4. IIPR and GRWG are the most liquid publicly traded options, but both face unique risks (tenant concentration and margin compression).
5. Diversification across sub-sectors is critical to mitigate client concentration and commoditization risks.
6. The ancillary market is growing at 22% CAGR, outpacing the broader cannabis industry's 15% growth rate.

Frequently Asked Questions

Question: Can I buy ancillary cannabis stocks in a regular brokerage account? Yes. Unlike plant-touching cannabis stocks, which some brokers restrict due to federal illegality, ancillary companies like IIPR and GRWG trade on the NYSE and Nasdaq without restriction. You can hold them in any standard brokerage account, IRA, or 401(k).

Question: Are ancillary cannabis companies profitable? Many are, but not all. IIPR and SMG are consistently profitable. GRWG has negative net income due to margin compression, but positive operating cash flow. The average ancillary cannabis company has a 12% net profit margin, compared to -8% for plant-touching operators.

Question: How does federal legalization affect ancillary companies? Paradoxically, federal legalization could be a negative catalyst. If cannabis is rescheduled to Schedule III, plant-touching companies gain access to tax deductions and banking, reducing their need for ancillary services. However, legalization would also expand the total addressable market, potentially offsetting any revenue loss.

Question: What is the best ETF for ancillary cannabis exposure? The AdvisorShares Pure US Cannabis ETF (MSOS) has approximately 15% ancillary holdings. The Global X Cannabis ETF (POTX) has about 25% ancillary exposure. For pure ancillary, consider the ETFMG Alternative Harvest ETF (MJ) , which holds 40% ancillary names after its 2023 rebalancing.

Question: Do ancillary cannabis companies pay dividends? Only IIPR pays a meaningful dividend (7.2% yield as of Q4 2024). Most ancillary companies reinvest cash flow into growth. However, as the sector matures, dividend initiation is expected within 3-5 years for firms like GRWG and SMG.

Question: How do I research ancillary cannabis companies? Start with SEC filings (10-K and 10-Q). Focus on revenue concentration, client retention rates, and cash flow from operations. Third-party resources like Viridian Capital Advisors and Cannabis Benchmarks provide industry-specific data. Avoid stock promotion sites; stick to audited financials.

Disclaimer: This article is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Investing in cannabis-related securities involves significant risks, including regulatory changes, market volatility, and potential total loss of capital. Consult a licensed financial advisor before making investment decisions.

For more insights, explore our guides on cannabis REITs and marijuana stock volatility.